BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26268528)

  • 1. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
    Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
    Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
    Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
    Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
    Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
    Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
    Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.
    Scheper GC; Morrice NA; Kleijn M; Proud CG
    Mol Cell Biol; 2001 Feb; 21(3):743-54. PubMed ID: 11154262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties.
    Parra JL; Buxadé M; Proud CG
    J Biol Chem; 2005 Nov; 280(45):37623-33. PubMed ID: 16162500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
    Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
    Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation.
    Gopaul K; Koorbanally NA
    Expert Opin Ther Pat; 2016 Aug; 26(8):861-9. PubMed ID: 27146589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
    Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Development of MNK Inhibitors as Therapeutic Agents.
    Xu W; Kannan S; Verma CS; Nacro K
    J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.
    Matsui Y; Yasumatsu I; Yoshida KI; Iimura S; Ikeno Y; Nawano T; Fukano H; Ubukata O; Hanzawa H; Tanzawa F; Isoyama T
    Acta Crystallogr F Struct Biol Commun; 2018 Mar; 74(Pt 3):156-160. PubMed ID: 29497019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2.
    Knauf U; Tschopp C; Gram H
    Mol Cell Biol; 2001 Aug; 21(16):5500-11. PubMed ID: 11463832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
    Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
    Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.